Obituaries
PGe
PG Store
Archives
Classifieds
Classified
Events
Jobs
Real Estate
Legal Notices
Pets
MENU
SUBSCRIBE
LOGIN
REGISTER
LOG OUT
MY PROFILE
Home
News
Local
Sports
Opinion
A&E
Life
Business
Contact Us
NEWSLETTERS
MENU
ACCOUNT
Subscribe
Login
Register
Log out
My Profile
Subscriber Services
Search
SECTIONS
HOME
Homepage
This Just In
Chats
Weather
Traffic
Event Guide
PG Store
PGe
Video
Photos
The Digs
RSS Feeds
NEWS
News Home
COVID-19
World
Nation
State
Obituaries
News Obituaries
Politics
Education
Portfolio
Science
Health & Wellness
Environment
Aging Edge
Transportation
Faith & Religion
Crimes & Courts
Social Services
LOCAL
Local Home
Region
City
North
East
West
South
Washington
Westmoreland
The Neighborhood
Obituaries
Classifieds
Legal Notices
Real Estate
SPORTS
Sports Home
Steelers
Penguins
Pirates
Sports Columns
Gene Collier
Ron Cook
Joe Starkey
Paul Zeise
High School Sports
College Sports
Pitt
Penn State
WVU
NCAA
NFL
MLB
NBA
NHL
North Shore Drive Podcast
OPINION
Opinion Home
Editorials
Letters
Op-Ed Columns
PG Columnists
Insight
A&E
A&E Home
Celebrities
Movies
TV & Radio
Music
Concert Listings
Theatre & Dance
Art & Architecture
Books
Events
LIFE
Life Home
Food
Buying Here
Homes & Gardens
Style & Fashion
Travel
Restaurants
Seen
goodness
Random Acts of Kindness
Pets
Beer Me
Outdoors
Holidays
BUSINESS
Business Home
Your Money
Wheels
Workzone
Business Health
Tech News
Building PGH
Powersource
Business / Law
Top Workplaces
Business of Pittsburgh
Consumer Alerts
OTHER
PGe
NEWSLETTERS
PG STORE
ARCHIVES
CLASSIFIEDS
OBITUARIES
JOBS
LEGAL NOTICES
REAL ESTATE
CLASSIFIEDS
EVENTS
PETS
CONTACT US / FAQ
CONTACT US
ADVERTISING
CAREER OPPORTUNITIES
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
TG Therapeutics, Inc. - Common Stock
(NQ:
TGTX
)
27.90
+0.18 (+0.65%)
Streaming Delayed Price
Updated: 12:08 PM EST, Jan 13, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about TG Therapeutics, Inc. - Common Stock
< Previous
1
2
3
4
5
6
7
8
9
...
11
12
Next >
TG Therapeutics TGTX Q3 2025 Earnings Transcript
↗
November 27, 2025
TG Therapeutics TGTX Q3 2025 Earnings Transcript
Via
The Motley Fool
10 Health Care Stocks With Whale Alerts In Today's Session
↗
November 11, 2025
Via
Benzinga
TG Therapeutics Crumbles After Roche Unveils Its 'Unprecedented' Test Results
↗
November 10, 2025
Roche presented "unprecedented" test results for its multiple sclerosis treatment, putting pressure on rival TG Therapeutics.
Via
Investor's Business Daily
Hussman Sells Off All 21,000 CHKP Shares Valued At $4.65 Million
↗
November 03, 2025
Hussman Sells Off All 21,000 CHKP Shares Valued At $4.65 Million
Via
The Motley Fool
TG Therapeutics Stock Soars After Company Ups Guidance For Multiple Sclerosis Drug
↗
November 03, 2025
Via
Stocktwits
Earnings Scheduled For November 3, 2025
↗
November 03, 2025
Via
Benzinga
Earnings Preview For TG Therapeutics
↗
October 31, 2025
Via
Benzinga
TG Therapeutics Board Authorizes New $100M Share Repurchase Program
↗
September 03, 2025
Via
Stocktwits
10 Health Care Stocks Whale Activity In Today's Session
↗
November 03, 2025
Via
Benzinga
Top Stocks With Earnings This Week: Joby, IonQ, AMD and More
↗
November 03, 2025
Retail investors are preparing for another busy week of earnings season with more than 1,600 companies set to report through Friday.
Via
Benzinga
Earnings Scheduled For August 4, 2025
↗
August 04, 2025
Via
Benzinga
What's Next: TG Therapeutics's Earnings Preview
↗
August 01, 2025
Via
Benzinga
Highly Watched TG Therapeutics Smashes Profit Views — With A Caveat
↗
November 03, 2025
TG Therapeutics stock rose early Monday on better-than-expected earnings.
Via
Investor's Business Daily
Topics
Earnings
Small-Cap Biotech Climb Bio's Lead Drug Candidate Has Larger Long-Term Opportunity
↗
October 16, 2025
William Blair assigns Climb Bio an Outperform rating, projecting peak sales of $1.9 billion and long-term growth for its therapy pipeline.
Via
Benzinga
TG THERAPEUTICS INC (NASDAQ:TGTX) Shows High Growth Momentum and Technical Breakout Setup
↗
October 07, 2025
TG Therapeutics (TGTX) shows explosive EPS growth up to 1,300% and strong sales momentum. With a perfect 10 technical rating and a bullish chart setup, it's a high-growth stock to watch.
Via
Chartmill
10 Health Care Stocks Whale Activity In Today's Session
↗
October 01, 2025
Via
Benzinga
TG Therapeutics CEO Voices Strong Conviction In Briumvi With New $100 Million Buyback
↗
September 03, 2025
TG Therapeutics' stock rose after completing a $100 million buyback and approving another $100 million plan, reinforcing confidence in Briumvi and growth prospects.
Via
Benzinga
TG Therapeutics Stock Tumbles 15% After Disappointing Q2, But Company Reaffirms Confidence In Multiple Sclerosis Drug
↗
August 04, 2025
The company raised its Briumvi U.S. net product revenue target to $570 million to $575 million for the full year 2025, up from its previous guidance of $560 million.
Via
Stocktwits
Topics
Earnings
Crude Oil Falls 1.5%; ON Semiconductor Shares Plunge After Q2 Results
↗
August 04, 2025
Via
Benzinga
Briumvi's Strong Sales Can't Stop TG Therapeutics Stock Slide
↗
August 04, 2025
TG Therapeutics missed Q2 earnings and revenue expectations but raised its 2025 Briumvi sales guidance following strong global growth.
Via
Benzinga
TG Therapeutics Q2 Revenue Up 91%
↗
August 04, 2025
Via
The Motley Fool
Topics
Intellectual Property
Why Top 3% Stock TG Therapeutics Crashed Despite Raising Its 2025 Outlook
↗
August 04, 2025
The company makes a multiple sclerosis treatment called Briumvi that rivals a drug from Roche.
Via
Investor's Business Daily
Traders are paying attention to the gapping stocks in Monday's session.
↗
August 04, 2025
Let's delve into the US markets on Monday and uncover the stocks that are experiencing notable gaps in today's session. Below, you'll find the gap up and gap down stocks.
Via
Chartmill
TG Therapeutics Inc (NASDAQ:TGTX) Reports Mixed Q2 2025 Results, Raises Full-Year BRIUMVI Revenue Guidance
↗
August 04, 2025
TG Therapeutics reported mixed Q2 2025 results, missing revenue and EPS estimates but raising full-year BRIUMVI sales guidance. Shares dipped slightly as investors weighed the outlook.
Via
Chartmill
TG THERAPEUTICS INC (NASDAQ:TGTX) – A High Growth Momentum Stock with Strong Technical Setup
↗
July 17, 2025
TG THERAPEUTICS INC (NASDAQ:TGTX) shows strong earnings momentum and a bullish technical setup, making it a candidate for high-growth investors. The stock has solid revenue growth, improving margins,...
Via
Chartmill
TG THERAPEUTICS INC (NASDAQ:TGTX) - A High-Growth Stock Meeting Minervini's Trend Template
↗
July 12, 2025
TG Therapeutics (TGTX) meets Minervini's Trend Template with strong technicals and high-growth fundamentals, including 1,300% EPS growth and 90% revenue expansion. A breakout above $37.27 could signal...
Via
Chartmill
Cramer Backs This Mining Giant After $1.6B Bet
↗
July 01, 2025
Jim Cramer recommends buying Rio Tinto due to its high yield. TG Therapeutics is also a buy, with strong first-quarter sales and potential for market share growth.
Via
Benzinga
TG THERAPEUTICS INC (NASDAQ:TGTX) - A High Growth Momentum Stock with Strong Technical Setup
↗
June 25, 2025
TG Therapeutics (TGTX) shows strong earnings momentum with 142% EPS growth and a bullish technical setup, making it a candidate for high-growth investors.
Via
Chartmill
TG Therapeutics Boosts Retail Sentiment With Q1 Revenue Beat Even As Stock Tumbles On Profit Miss, Conservative Outlook
↗
May 05, 2025
Investors are optimistic about the company’s prospects, particularly in the multiple sclerosis market, despite challenges from competitors.
Via
Stocktwits
TG Therapeutics Falls Short On Earnings, But Briumvi Sales Steal the Show
↗
May 05, 2025
TG Therapeutics posts Q1 profit and nearly doubles revenue, driven by rising Briumvi sales and higher full-year guidance for 2025.
Via
Benzinga
< Previous
1
2
3
4
5
6
7
8
9
...
11
12
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story
Your e-mail:
Friends e-mail:
Submit
